title: Characterization of a human monoclonal antibody obtained after immunization with plasma vaccine and a booster with recombinant-DNA hepatitis B vaccine.
abstract: A human monoclonal antibody type IgG4, designated 1Ff4, was obtained by Epstein Barr virus transformation of peripheral blood lymphocytes from a hepatitis B vaccinee (HB-VAX: plasma-derived vaccine) after one boost of yeast recombinant DNA derived vaccine (Engerix-B). 1Ff4 binds preferentially to HBsAg/adw(2) and HBsAg/ayw(1). In binding experiments, it competes with antibodies induced by vaccination with HB-VAX-DNA (yeast recombinant) and HB-VAX (plasma-derived vaccine). 1Ff4 competes in part with a monoclonal antibody for the w/r region. Partial inhibition of binding of HBsAg/adw(2) to solid phase anti-HBs was detected, resembling inhibition obtained using other human monoclonal specific for the "a"-loop. 1Ff4 does not bind to linear peptides covering the two "a"-loops or to an adw(2)/G145R mutant, its binding to wild type HBsAg strongly depends on the presence of disulphide bonds. In a large series of HBsAg-positive samples from an endemic area, 1Ff4 antibodies were successfully used to discriminate between an adw(2) and an adrq+ strain. The characterisation of 1Ff4 and other human monoclonal anti-HBs antibodies may help to understand the fine specificity of protective antibodies elicited by immunization.
authors.affiliation: Department of Virology, Erasmus University Rotterdam, Rotterdam, The Netherlands. Heijtink@viro.fgg.eur.nl
authors.forename: R A
authors.initials: RA
authors.lastname: Heijtink
authors.forename: J
authors.initials: J
authors.lastname: Kruining
authors.forename: P
authors.initials: P
authors.lastname: van Bergen
authors.forename: S
authors.initials: S
authors.lastname: de Rave
authors.forename: J
authors.initials: J
authors.lastname: van Hattum
authors.forename: M
authors.initials: M
authors.lastname: Schutten
authors.forename: A D M E
authors.initials: AD
authors.lastname: Osterhaus
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology*; D001667:Binding, Competitive; D018985:Epitopes, B-Lymphocyte / Q000276:immunology; D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000276:immunology*; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006801:Humans; D007114:Immunization; D007117:Immunization, Secondary; D012996:Solutions; D014614:Vaccines, Synthetic / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; C075654:Engerix-B; D018985:Epitopes, B-Lymphocyte; C075659:HB-VAX; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D012996:Solutions; D014614:Vaccines, Synthetic